Premium
In vivo evaluation of bioprinted prevascularized bone tissue
Author(s) -
Rukavina Patrick,
Koch Fritz,
Wehrle Maximilian,
Tröndle Kevin,
Björn Stark G.,
Koltay Peter,
Zimmermann Stefan,
Zengerle Roland,
Lampert Florian,
Strassburg Sandra,
Finkenzeller Günter,
Simunovic Filip
Publication year - 2020
Publication title -
biotechnology and bioengineering
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.136
H-Index - 189
eISSN - 1097-0290
pISSN - 0006-3592
DOI - 10.1002/bit.27527
Subject(s) - 3d bioprinting , biomedical engineering , tissue engineering , umbilical vein , mesenchymal stem cell , matrix (chemical analysis) , adipose tissue , transplantation , microbiology and biotechnology , chemistry , biology , in vitro , medicine , surgery , biochemistry , chromatography
Bioprinting can be considered as a progression of the classical tissue engineering approach, in which cells are randomly seeded into scaffolds. Bioprinting offers the advantage that cells can be placed with high spatial fidelity within three‐dimensional tissue constructs. A decisive factor to be addressed for bioprinting approaches of artificial tissues is that almost all tissues of the human body depend on a functioning vascular system for the supply of oxygen and nutrients. In this study, we have generated cuboid prevascularized bone tissue constructs by bioprinting human adipose‐derived mesenchymal stem cells (ASCs) and human umbilical vein endothelial cells (HUVECs) by extrusion‐based bioprinting and drop‐on‐demand (DoD) bioprinting, respectively. The computer‐generated print design could be verified in vitro after printing. After subcutaneous implantation of bioprinted constructs in immunodeficient mice, blood vessel formation with human microvessels of different calibers could be detected arising from bioprinted HUVECs and stabilization of human blood vessels by mouse pericytes was observed. In addition, bioprinted ASCs were able to synthesize a calcified bone matrix as an indicator of ectopic bone formation. These results indicate that the combined bioprinting of ASCs and HUVECs represents a promising strategy to produce prevascularized artificial bone tissue for prospective applications in the treatment of critical‐sized bone defects.